Testing Experimental Medication in Healthy Subjects
common.study.values.description
“Exploratory Evaluation of [11C]-NOP46”
This is an open-label, single center design. In the first stage, five (5) healthy individuals will receive a microdose (10A?g) of [11C]-NOP46, immediately followed by whole body positron emission tomography (PET)/computed tomography (CT) to determine dosimetry and perform an initial safety evaluation of the radiotracer. If no toxicities develop, then the investigation will move to the second stage, in which thirty (30) patients with chronic pain will receive a microdose of [11C]-NOP46 followed by PET/CT of region of interests.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - [11C]-NOP46
Subjects will receive a microdose (≤10 µg) of [11C]-NOP46.
Radiation - PET/CT scan
After subjects receive a microdose of [11C]-NOP46, whole body PET/CT scan(s) will be performed to determine dosimetry and perform an initial safety evaluation of the radiotracer in Stage 1 and region of interests in Stage 2.
participant.views.study.view.additional
participant.views.study.view.scientific-title
Exploratory Evaluation of [11C]-NOP46 Pharmacokinetics With Positron Emission Tomography (PET)
common.study.values.clinical-trial-id
NCT03705819
participant.views.study.view.id
dR61qd
